News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
708,451 Results
Type
Article (41680)
Company Profile (279)
Press Release (666492)
Multimedia
Podcasts (53)
Webinars (12)
Section
Business (206415)
Career Advice (2021)
Deals (35688)
Drug Delivery (99)
Drug Development (82047)
Employer Resources (172)
FDA (16375)
Job Trends (14987)
News (349126)
Policy (33142)
Tag
Academia (2618)
Accelerated approval (5)
Adcomms (21)
Allergies (88)
Alliances (50387)
ALS (92)
Alzheimer's disease (1399)
Antibody-drug conjugate (ADC) (126)
Approvals (16370)
Artificial intelligence (261)
Autoimmune disease (22)
Automation (16)
Bankruptcy (364)
Best Places to Work (11706)
BIOSECURE Act (21)
Biosimilars (111)
Biotechnology (198)
Bladder cancer (81)
Brain cancer (27)
Breast cancer (280)
Cancer (2295)
Cardiovascular disease (176)
Career advice (1688)
Career pathing (30)
CAR-T (154)
Cell therapy (437)
Cervical cancer (20)
Clinical research (66735)
Collaboration (848)
Company closure (1)
Compensation (533)
Complete response letters (21)
COVID-19 (2640)
CRISPR (41)
C-suite (244)
Cystic fibrosis (101)
Data (2223)
Decentralized trials (2)
Denatured (20)
Depression (44)
Diabetes (272)
Diagnostics (6424)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (122)
Drug pricing (102)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (87026)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (113850)
Executive appointments (730)
FDA (17654)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (759)
Gene editing (106)
Generative AI (20)
Gene therapy (315)
GLP-1 (720)
Government (4545)
Grass and pollen (4)
Guidances (67)
Healthcare (19001)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (123)
Indications (30)
Infectious disease (2785)
Inflammatory bowel disease (141)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (97)
Interviews (312)
IPO (16619)
IRA (41)
Job creations (3691)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (477)
Leadership (17)
Legal (7984)
Liver cancer (77)
Lung cancer (326)
Lymphoma (155)
Machine learning (7)
Management (58)
Manufacturing (315)
MASH (67)
Medical device (13481)
Medtech (13486)
Mergers & acquisitions (19615)
Metabolic disorders (689)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (92)
Neuropsychiatric disorders (27)
Neuroscience (1942)
NextGen: Class of 2025 (6593)
Non-profit (4547)
Now hiring (39)
Obesity (366)
Opinion (212)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (84)
Parkinson's disease (149)
Partnered (22)
Patents (236)
Patient recruitment (113)
Peanut (49)
People (57936)
Pharmaceutical (67)
Pharmacy benefit managers (18)
Phase I (20861)
Phase II (29367)
Phase III (21868)
Pipeline (1209)
Policy (145)
Postmarket research (2594)
Preclinical (8864)
Press Release (71)
Prostate cancer (106)
Psychedelics (31)
Radiopharmaceuticals (248)
Rare diseases (387)
Real estate (6049)
Recruiting (65)
Regulatory (22731)
Reports (46)
Research institute (2381)
Resumes & cover letters (350)
Rett syndrome (5)
RNA editing (5)
RSV (43)
Schizophrenia (71)
Series A (132)
Series B (85)
Service/supplier (12)
Sickle cell disease (54)
Special edition (14)
Spinal muscular atrophy (149)
Sponsored (30)
Startups (3643)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (41)
The Weekly (31)
Vaccines (719)
Venture capitalists (41)
Weight loss (235)
Women's health (35)
Worklife (16)
Date
Last 7 days (908)
Last 30 days (2516)
Last 365 days (32991)
2025 (10874)
2024 (35653)
2023 (40470)
2022 (51663)
2021 (56203)
2020 (54553)
2019 (47053)
2018 (35493)
2017 (32606)
2016 (32030)
2015 (38108)
2014 (31822)
2013 (26821)
2012 (29042)
2011 (29744)
2010 (27769)
Location
Africa (736)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (38725)
Australia (6307)
California (6169)
Canada (2022)
China (530)
Colorado (268)
Connecticut (277)
Delaware (151)
Europe (83403)
Florida (914)
Georgia (206)
Idaho (57)
Illinois (539)
India (26)
Indiana (312)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (922)
Massachusetts (4614)
Michigan (220)
Minnesota (404)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1743)
New Mexico (28)
New York (1761)
North Carolina (1093)
North Dakota (9)
Northern California (2690)
Ohio (207)
Oklahoma (14)
Oregon (35)
Pennsylvania (1387)
Puerto Rico (12)
Rhode Island (33)
South America (1117)
South Carolina (23)
South Dakota (1)
Southern California (2319)
Tennessee (101)
Texas (912)
United States (23442)
Utah (182)
Virginia (147)
Washington D.C. (63)
Washington State (554)
West Virginia (3)
Wisconsin (54)
708,451 Results for "biologics inc nc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
NextCure, Inc. today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
May 30, 2024
·
5 min read
Business
Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company based in Japan, announced that its board of directors has approved plans to invest up to $530 million to build a new, state-of-the-art manufacturing facility in Sanford, North Carolina.
June 10, 2024
·
4 min read
Press Releases
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
March 7, 2025
·
6 min read
Press Releases
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
April 10, 2025
·
15 min read
BioCapital
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
NextCure, Inc. (Nasdaq: NXTC) today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4 in Chicago.
April 24, 2024
·
2 min read
Press Releases
Solvias to Speak at Festival of Biologics 2025 on Building Robust CMC Assays for Biologic Therapies
April 23, 2025
·
2 min read
Press Releases
MustGrow Signs Exclusive Distribution Agreement with Adjuvants Plus Inc. for Biological Product Line
February 11, 2025
·
8 min read
Press Releases
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
December 23, 2024
·
4 min read
Press Releases
Vivex Biologics, Inc. Provides Enrollment Update for its ASCEND Study Examining Whether Supplementing Discs with VIA Disc NP™ Reduces Pain and/or Improves Function in Patients with Symptomatic Disc Degeneration
April 9, 2025
·
2 min read
Press Releases
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
November 5, 2024
·
5 min read
1 of 70,846
Next
